William Jarosz
Director/Board Member at SATELLOS BIOSCIENCE INC.
Net worth: 640 054 $ as of 2024-03-30
Profile
William Jarosz is currently the Executive Director at Satellos Bioscience, Inc. and a Senior Advisor at Cartesian Capital Group LLC.
Previously, he was the Chief Executive Officer at iCo Therapeutics, Inc. from 2020 to 2021.
He also held Managing Director positions at AIG Brunswick Millennium Fund and PineBridge Capital Partners LLC from 1997 to 2005.
Additionally, he was an Executive Director at Satellos Bioscience, Inc. Mr. Jarosz has graduate degrees from The University of Montana, The Fletcher School, and Harvard Law School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
SATELLOS BIOSCIENCE INC
1.52% | 2023-05-31 | 1,711,374 ( 1.52% ) | 640 054 $ | 2024-03-30 |
William Jarosz active positions
Companies | Position | Start |
---|---|---|
SATELLOS BIOSCIENCE INC. | Director/Board Member | - |
Cartesian Capital Group LLC
Cartesian Capital Group LLC Investment ManagersFinance Cartesian Capital Group LLC (Cartesian Capital) is a private equity firm founded in 2006 by Peter Yu, Thomas Armstrong and Paul Pizzani. The firm is headquartered in New York. | Consultant / Advisor | - |
Former positions of William Jarosz
Companies | Position | End |
---|---|---|
SATELLOS BIOSCIENCE INC. | Chief Executive Officer | 2020-12-31 |
PineBridge Capital Partners LLC
PineBridge Capital Partners LLC Investment ManagersFinance PineBridge Capital Partners LLC is a private equity firm located in New York City. The firm is a subsidiary of PineBridge Private Equity Group Partners and their ultimate parent is Hong Kong-based Pacific Century Group. | Chief Executive Officer | 2004-12-31 |
AIG Brunswick Millennium Fund
AIG Brunswick Millennium Fund Investment ManagersFinance AIG Brunswick Millennium Fund seeks investment opportunities in companies located in Russia, the Baltic States and other nations of the former Soviet Union. The fund targets companies operating in large infrastructure projects include power, transportation, natural resource development and related industries. It provides financing for buyout capital requirements with a minimum investment size of $7 million. | Corporate Officer/Principal | 2004-12-31 |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Training of William Jarosz
The University of Montana | Graduate Degree |
The Fletcher School | Graduate Degree |
Harvard Law School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SATELLOS BIOSCIENCE INC. | Health Technology |
Private companies | 5 |
---|---|
AIG Brunswick Millennium Fund
AIG Brunswick Millennium Fund Investment ManagersFinance AIG Brunswick Millennium Fund seeks investment opportunities in companies located in Russia, the Baltic States and other nations of the former Soviet Union. The fund targets companies operating in large infrastructure projects include power, transportation, natural resource development and related industries. It provides financing for buyout capital requirements with a minimum investment size of $7 million. | Finance |
PineBridge Capital Partners LLC
PineBridge Capital Partners LLC Investment ManagersFinance PineBridge Capital Partners LLC is a private equity firm located in New York City. The firm is a subsidiary of PineBridge Private Equity Group Partners and their ultimate parent is Hong Kong-based Pacific Century Group. | Finance |
iCo Therapeutics, Inc.
iCo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology iCo Therapeutics, Inc. is a canadian biotechnology company. It engages in the business of identification, development and commercialization of drug candidates to treat ocular and infectious diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA. | Health Technology |
Cartesian Capital Group LLC
Cartesian Capital Group LLC Investment ManagersFinance Cartesian Capital Group LLC (Cartesian Capital) is a private equity firm founded in 2006 by Peter Yu, Thomas Armstrong and Paul Pizzani. The firm is headquartered in New York. | Finance |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
- Stock Market
- Insiders
- William Jarosz